Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463027 | 0.79 | ADK (0.48) | ADKDYRK1ALRRK2ADORA2AADORA1 | |
| SCHEMBL6430725 | 0.78 | EIF2AK3 (0.46) | DYRK1ALRRK2ADORA2AADORA1EIF2AK3 | |
| SCHEMBL13192053 | 0.78 | ADORA2A (0.46) | DYRK1ALRRK2ADORA2AADORA1ADORA2B | |
| SCHEMBL868823 | 0.78 | ADK (0.49) | ADKDYRK1AADORA2AADORA1ADORA2B | |
| SCHEMBL1585102 | 0.78 | ADK (0.49) | ADKDYRK1ALRRK2ADORA2AADORA1 | |
| SCHEMBL19679364 | 0.77 | SRC (0.57) | ADKEGFRSRCKDRPI4KA | |
| SCHEMBL870102 | 0.77 | PIK3CD (0.51) | ADKADORA2AADORA1ADORA2BPIK3CD | |
| SCHEMBL25640018 | 0.76 | ADK (0.34) | ADKDYRK1AADORA2AADORA1ADORA2B | |
| SCHEMBL30582603 | 0.76 | EIF2AK3 (0.43) | DYRK1AADORA2AADORA1ADORA2BSRC | |
| SCHEMBL26107539 | 0.76 | EIF2AK3 (0.43) | DYRK1AADORA2AADORA1ADORA2BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722216-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12590064-B2 | Substituted benzamides for inhibiting perk activity | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119894900-A | Pyrrolo pyrimidine derivative and application thereof in medicine | 康百达（四川）生物医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025067484-A1 | CRYSTAL FORMS AND SALTS OF SPIROBICYCLIC COMPOUND | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | ADK 1509/4885DYRK1A 3136/4885LRRK2 19/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | ADK 1509/4885DYRK1A 3136/4885LRRK2 19/4885 |
| US-12590064-B2 | Substituted benzamides for inhibiting perk activity | EIF2AK3, EIF2AK1, EIF2AK4 | ADK 672/4885DYRK1A 666/4885LRRK2 392/4885 |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | ADK 1193/4885DYRK1A 271/4885LRRK2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.